FR941202-0-00028 FR941202-0-00001 §35.11 License required. (a) A person shall not manufacture, produce, acquire, receive, possess, use, or transfer byproduct material for medical use except in accordance with a specific license issued by the Commission or an Agreement State, or as allowed in paragraph (b) or (c) of this section. * * * * * (c) An individual may prepare unsealed byproduct material for medical use in accordance with the regulations in this chapter under the supervision of an authorized nuclear pharmacist or authorized user as provided in §35.25, unless prohibited by license condition. 16. In §35.12, paragraph (e) is added to read as follows: §35.12 Application for license, amendment, or renewal. * * * * * (e) An applicant that satisfies the requirements specified in 10 CFR 33.13 may apply for a Type A specific license of broad scope. 17. In §35.13, paragraph (b) is revised to read as follows: §35.13 License amendments. * * * * * (b) Before it permits anyone to work as an authorized user or authorized nuclear pharmacist under the license, except an individual who is: (1) An authorized user certified by the organizations specified in paragraph (a) of §35.910, 35.920, 35.930, 35.940, 35.950, or 35.960; (2) An authorized nuclear pharmacist certified by the organization specified in paragraph (a) of §35.980; (3) Identified as an authorized user or an authorized nuclear pharmacist on a Commission or Agreement State license that authorizes the use of byproduct material in medical use or in the practice of nuclear pharmacy, respectively; or (4) Identified as an authorized user or an authorized nuclear pharmacist on a permit issued by a Commission or Agreement State specific licensee of broad scope that is authorized to permit the use of byproduct material in medical use or in the practice of nuclear pharmacy, respectively. * * * * * 18. Section 35.14 is revised to read as follows: §35.14 Notifications. (a) A licensee shall provide to the Commission a copy of the board certification, the Commission or Agreement State license, or the permit issued by a licensee of broad scope for each individual no later than 30 days after the date that the licensee permits the individual to work as an authorized user or an authorized nuclear pharmacist pursuant to §35.13 (b)(1) through (b)(4). (b) A licensee shall notify the Commission by letter no later than 30 days after: (1) An authorized user, an authorized nuclear pharmacist, Radiation Safety Officer, or teletherapy physicist permanently discontinues performance of duties under the license or has a name change; or (2) The licensee's mailing address changes. (c) The licensee shall mail the documents required in this section to the appropriate address identified in §30.6 of this chapter. 19. Section 35.15 is added to read as follows: §35.15 Exemptions regarding Type A specific licenses of broad scope. A licensee possessing a Type A specific license of broad scope for medical use is exempt from the following: (a) The provisions of §35.13(b); (b) The provisions of §35.13(e) regarding additions to or changes in the areas of use only at the addresses specified in the license; (c) The provisions of §35.14(a); and (d) The provisions of §35.14(b)(1) for an authorized user or an authorized nuclear pharmacist. 20. In §35.22, paragraph (b)(2) is revised to read as follows: §35.22 Radiation Safety Committee. * * * * * (b) *␣*␣* (2)(i) Review, on the basis of safety and with regard to the training and experience standards in Subpart J of this part, and approve or disapprove any individual who is to be listed as an authorized user, an authorized nuclear pharmacist, the Radiation Safety Officer, or a teletherapy physicist before submitting a license application or request for amendment or renewal; or (ii) Review, pursuant to §35.13 (b)(1) through (b)(4), on the basis of the board certification, the license, or the permit identifying an individual, and approve or disapprove any individual prior to allowing that individual to work as an authorized user or authorized nuclear pharmacist; * * * * * 21. In §35.25, paragraph (b) is redesignated as paragraph (c) and a new paragraph (b) is added to read as follows. §35.25 Supervision. * * * * * (b) A licensee that permits the preparation of byproduct material for medical use by an individual under the supervision of an authorized nuclear pharmacist or physician who is an authorized user, as allowed by §35.11(c), shall: (1) Instruct the supervised individual in the preparation of byproduct material for medical use and the principles of and procedures for radiation safety and in the licensee's written quality management program, as appropriate to that individual's use of byproduct material; (2) Require the supervised individual to follow the instructions given pursuant to paragraph (b)(1) of this section and to comply with the regulations of this chapter and license conditions; and
